New insights and results from the RE-LY trial

被引：0
|
作者：
不详
机构：
来源：
CARDIOVASCULAR JOURNAL OF AFRICA | 2011年 / 22卷 / 05期
关键词：
ATRIAL-FIBRILLATION; DABIGATRAN; WARFARIN;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：284 / 286
页数：2
相关论文
共 50 条
  • [1] Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial
    Proietti, M.
    Hijazi, Z.
    Andersson, U.
    Connolly, S. J.
    Eikelboom, J. W.
    Ezekowitz, M. D.
    Lane, D. A.
    Oldgren, J.
    Roldan, V.
    Yusuf, S.
    Wallentin, L.
    JOURNAL OF INTERNAL MEDICINE, 2018, 283 (03) : 282 - 292
  • [2] Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial
    Khoo, Chee W.
    Lip, Gregory Y. H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (04) : 685 - 687
  • [3] Comparison of Dabigatran versus Warfarin in Diabetic Patients with Atrial Fibrillation: Results from the RE-LY Trial
    Darius, Harald
    Clemens, Andreas
    Healey, Jeff S.
    Avezum, Alvaro
    Nagarakanti, Rangadham
    Chin, Ashley
    Noack, Herbert
    Connolly, Stuart
    CIRCULATION, 2012, 126 (21)
  • [4] Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial
    Brambatti, Michela
    Darius, Harald
    Oldgren, Jonas
    Clemens, Andreas
    Noack, Herbert H.
    Brueckmann, Martina
    Yusuf, Salim
    Wallentin, Lars
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Healey, Jeff S.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 196 : 127 - 131
  • [5] Benefits of Dabigatran versus Warfarin in Hypertensive Patients With Atrial Fibrillation: Results From The Re-ly Trial
    Nagarakanti, Rangadham
    Connolly, Stuart
    Brueckmann, Martina
    Hart, Robert G.
    Reilly, Paul
    Noack, Herbert
    Clemens, Andreas
    Wallentin, Lars
    Yusuf, Salim
    Ezekowitz, Michael D.
    CIRCULATION, 2013, 128 (22)
  • [6] A Review of the Clinical Subgroup Analyses From the RE-LY Trial
    Kumar, Rohit
    Rahman, Aref M.
    Henry, Brian L.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2016, 17 (1-2) : 40 - 48
  • [7] Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial
    Paikin, Jeremy S.
    Haroun, Michelle J.
    Eikelboom, John W.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2011, 9 (03) : 279 - 286
  • [8] Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial
    Boehm, Michael
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Eikelboom, John W.
    Hohnloser, Stefan H.
    Reilly, Paul A.
    Schumacher, Helmut
    Brueckmann, Martina
    Schirmer, Stephan H.
    Kratz, Mario T.
    Yusuf, Salim
    Diener, Hans-Christoph
    Hijazi, Ziad
    Wallentin, Lars
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (23) : 2481 - 2493
  • [9] Dabigatran Versus Warfarin in Very Elderly Patients with Atrial Fibrillation: Results from the RE-LY Trial
    Coppens, Michiel
    Eikelboom, John
    Ezekowitz, Michael
    Clemens, Andreas
    Healy, Jeff
    Wallentin, Lars
    Noack, Herbert
    Yusuf, Salim
    Connolly, Stuart
    CIRCULATION, 2012, 126 (21)
  • [10] Switching patients from warfarin to dabigatran therapy: To RE-LY or not to rely
    Sawaya, Fadi J.
    Musallam, Khaled M.
    Arnaout, Samir
    Rabah, Ali
    Sawaya, Jaber
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 154 (02) : E27 - E28
12345